The advisory group of the European Medicines Agency (EMA) and the Committee for Medicinal Products for Human Use (CHMP), recommended on Friday the approval of a new drug against migraine "Ajovy," produced by Teva Pharmaceutical Industries Ltd.
The final decision by the European Commission can be expected within 60 days, and is likely to follow the recommendation.
The United States Food and Drug Administration (FDA) approved the drug in September last year.
Teva's shares rose almost 1.5% in premarket trade on Wall Street after the recommendation was announced.
